The purpose of this study is to determine whether mindfulness-based cognitive therapy (MBCT) and cognitive behavioral therapy (CBT) are effective in reducing depressive symptoms in patients after cancer
Cancer patients are prone to develop depressive symptoms, even after curative treatment. Conventional therapies such as cognitive behavioral therapy (CBT) and mindfulness-based cognitive therapy (MBCT) are frequently used for reducing these depressive symptoms in patients with medical conditions. However, until now evidence from proper designed randomized controlled trials regarding the effectiveness of both interventions in cancer survivors, is lacking. Therefore, our longitudinal study aims to investigate the effectiveness of CBT and MBCT in reducing depressive symptoms in cancer survivors. In addition, potential moderators and mediators of each intervention will be explored.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
192
The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
UMCG
Groningen, Provincie Groningen, Netherlands
RECRUITINGChange in severity of depressive symptoms
Severity of depressive symptoms will be assessed with the Beck Depression Inventory-II (BDI-II)
Time frame: pre-treatment (baseline) to post-treatment (approximately 3 months after baseline) and 3- and 9-month follow-up
Change in generalized anxiety
Generalized anxiety is measured by the Generalised Anxiety Disorder Assessment (GAD 7)
Time frame: pre-treatment (baseline) to post-treatment (approximately 3 months after baseline) and 3- and 9-month follow-up
Change in well-being
Well-being is measured by the WHO Well-being Index (WHO-5)
Time frame: pre-treatment (baseline) to post-treatment (approximately 3 months after baseline) and 3- and 9-month follow-up
Change in fear of recurrence
Fear of recurrence will be measured by Concerns About Recurrence Scale (CARS)
Time frame: pre-treatment (baseline) to post-treatment (approximately 3 months after baseline) and 3- and 9-month follow-up
Change in fatigue
Fatigue is measured by the subsequent scale of the Multidimensional Fatigue Inventory (MFI-20)
Time frame: pre-treatment (baseline) to post-treatment (approximately 3 months after baseline) and 3- and 9-month follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.